Tyruko Injectable Product clinical trials

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

This study investigates whether starting a highly effective MS treatment, Natalizumab (Tyruko®), very soon after someone first shows symptoms can help repair nerve damage. It focuses on people with early signs of MS or a definite diagnosis.